Project Detail:
End-to-end commercial diligence for a Europe-focused pharmaceutical CDMOFunctional Areas:
Commercial / StrategyCompany Type:
Mid-sized CDMOTherapy Area:
Small Molecule Manufacturing (OTC & Rx)Problem Statement
A
private equity investor aimed to evaluate an acquisition in the CDMO space,
seeking clarity on market attractiveness, segment-level risks, and the target’s
competitive positioning and growth durability.
Our Approach
We applied a structured, outside-in lens to test the investment thesis:
- Mapped the small molecule CDMO market by dosage forms and value chain, identifying high-growth and defensible segments
- Assessed outsourcing behavior, including buyer criteria, decision processes, and key stakeholders
- Evaluated regulatory complexity and switching barriers across OTC vs. Rx portfolios
- Analyzed European market dynamics, including structural tailwinds, cost positioning, and COVID-related shifts
- Conducted targeted deep dives into key product segments, assessing growth outlook, competition, entry barriers, and demand–supply balance
- Reviewed exposure to risks such as patent cliffs, formulation changes, and evolving therapeutic trends
- Benchmarked the target’s positioning, highlighting differentiation, strengths, and gaps versus peers
Outcome
- Pinpointed priority growth segments aligned with favorable outsourcing trends
- Identified segment-specific risks impacting revenue visibility and margins
- Confirmed barriers supporting customer retention in select categories
- Clarified competitive positioning and sources of advantage
- Developed a focused investment view, outlining key upsides and diligence considerations